Study of NK1-receptor antagonist; aprepitant for prevention of nausea and emesis in patients receiving chemotherapy with irinotecan for gastric cancer.

Study of NK1-receptor antagonist; aprepitant for prevention of nausea and emesis in patients receiving chemotherapy with irinotecan for gastric cancer. - Effect of aprepitant in patient receiving chemotherapy with irinotecan for gastric cancer.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011962

Enrollment

Registered

2013-10-05

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients receiving first course of chemotherapy with irinotecan for gastric cancer. 2)UGT1A1 genotype: wild or hetero type 3) aged 20 years or more. 4) patents had carried out no adverse effect of prior chemotherapy. 5) written informed consent from the patients.

Exclusion criteria

Exclusion criteria: 1) patients with serious hepatic insufficiency or renal failure. 2) patients with emesis within 24 hours before first administrating of cisplatin. 3) patients who were administered antiemetic drugs within 48 hours before first administrating of cisplatin. 4) patients with emetic factor except for chemotherapy 5) patient who was intended radiation therapy

Design outcomes

Primary

Measure	Time frame
Ratio of complete response (defined as no emesis and no rescue treatment). [Time Frame: overall; 0-120hr after chemotherapy, acute phase; 0-24hr, delayed phase; 24-120hr].	—

Secondary

Measure	Time frame
1) ratio of patient without emesis. 2) ratio of patient without rescue treatment. 3) ratio of patient without nausea. 4) time to first emesis. 5) evaluation of volume of meal intake. 6) evaluation of QOL with Functional Living index-Emesis (FLIE) scale.	—

Countries

Japan

Contacts

Public ContactKatsunobu Oyama

Kanazawa University Gastroenterologic Surgery

oya-ma@staff.kanazawa-u.ac.jp076-265-2000

Outcome results